Aptus Pharma Gets BSE Nod for Major Share Issuance

Issue Size: 15,99,270 Equity Shares
Minimum Price: Rs 280 per share

Reader Takeaway: The in-principle approval clears a key hurdle for capital infusion, though strict compliance on trading restrictions remains mandatory.

What just happened

Aptus Pharma Limited has received the green light from BSE Limited for its proposed preferential issue. The exchange granted in-principle approval on October 30, 2026, enabling the company to issue 15,99,270 equity shares to both promoters and non-promoters. This move follows the shareholder authorization received during the company's Annual General Meeting on September 14, 2026.

Regulatory and Procedural Requirements

The BSE has imposed specific compliance mandates to ensure transparency throughout the issuance process. The company is required to uphold stringent internal controls, including obtaining written undertakings from all proposed allottees. These allottees must commit to refraining from any intra-day trading of Aptus Pharma shares until the final allotment process is concluded.

Furthermore, Aptus Pharma bears the responsibility for ensuring full adherence to the Companies Act, 2013, and SEBI’s ICDR regulations. Following the share allotment, the company must submit a formal listing application to the exchange within 20 days, accompanied by the required documentation and regulatory fees.

What to track next

Investors should watch for the official allotment date announcement and the company’s subsequent filing of the final listing application. The successful completion of this process will be a crucial indicator for the company’s capital structure and balance sheet strength moving forward.